By

Lundbeckfonden
Lund, Sweden, 13:00 CET 20 April 2018 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in BONESUPPORT HOLDING AB, Reg. No. 556802-2171, are hereby invited to attend the annual shareholders’ meeting (Sw. årsstämma) to be held...
Veloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company’s supplemental New Drug Application (sNDA) which seeks a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.  This indication is commonly...
The Lundbeck Foundation had a successful 2017 with continued growth in turnover and a record-high profit of DKK 3.9 billion before special items. The Lundbeck Foundation also awarded grants worth DKK 507 million to biomedical sciences research – the highest level in the foundation’s history. • Turnover climbed 5% from DKK 33,748 million in 2016...
Cambridge, UK and Indianapolis, US – 11 April 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has made substantial progress in expanding its US commercial operations for the...
The Society for Neuroscience will receive around 4.5 million Danish kroner from the Lundbeck Foundation over the next five years for further development of brain research’s leading knowledge portal – BrainFacts.org. The Lundbeck Foundation joins the exclusive company of the major foundations and institutions that have already entered a partnership with knowledge portal BrainFacts.org. BrainFacts.org...
–          Healthcare investment professional and rare disease advocate strengthens leadership team –          Imran Babar to help company continue accelerating new treatments for rare diseases Cambridge, Mass., April 9, 2018 – Cydan today announced that Imran A. Babar, PhD, has been named to the leadership team as chief business officer to help the company advance new and...
Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch), today announced that Jennifer Good, President and Chief Executive Officer, will present at Needham & Company’s 17th Annual Healthcare Conference. The presentation will take place in New York City on Tuesday, March 27 at 4:30 pm ET. About Trevi Therapeutics, Inc. Trevi...
Lund, Sweden, 08.00 CET, 21 March 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces that three papers based on the successful use of CERAMENT® G to treat bone infections were presented at the...
Positive Phase 3 Clinical Trial Published in Peer-reviewed Journal, Anesthesiology Cambridge, UK and Indianapolis, US – 15 March 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, announces that data...
Lund, Sweden, 08.00 CET, 13 March 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces that Emil Billbäck, its recently appointed Chief Executive Officer, purchased 60,000 shares in the Company at a price of...
1 2 3 8

News

Robust operating profit and record level of funds for grants
18. April 2018
The Lundbeck Foundation enters partnership with BrainFacts.org
10. April 2018
Four neuroscientists receive The Brain Prize for crucial research on Alzheimer’s
6. March 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge